Living Cell Technologies Clinical Trial Proves Positive For All The Type 1 Diabetes Patients
Living Cell Technologies Limited has today released the results of their DiabeCell(R) trials on Six patients with insulin dependent (type 1) diabetes. The company has released the results describing clinical benefit of the Company’s encapsulated porcine islet cells for the treatment of type 1 diabetes.
The trial shows that the six patients with insulin dependent diabetes have now received DiabeCell(R) implants. Five patients in the first group received the lowest dose of 5,000 islet equivalents (IEQ/kg) and two of them have received a second implant of the same dose. So far they received no side effect. The trial has been expanded to a second group of five patients and the sixth patient in the trial has been implanted with the higher dose of 10,000 IEQ/kg.
Improvement in blood glucose control in the group is reflected by the Mean glycated hemoglobin (HbA1c) level which fell from 8.5% pre-implant to 6.8% at the time of last measurement. The lowest patient response was a 10% maximum reduction in daily insulin requirement. The patient’s HbA1c dropped markedly however, from 10.1 to 7.3 following the implant. This result indicates better blood glucose control after treatment with DiabeCell(R) and continuous glucose monitoring has confirmed this.
Professor Elliott, LCT Medical Director, said,
“At this stage in the DiabeCell(R) trial clinical benefit has been observed in all five patients receiving the lowest dose which has far exceeded our expectations. In the first group, following DiabeCell(R) implants we have seen reductions in daily insulin requirements ranging from 23% to as much as 100% while maintaining good control of blood glucose levels in four out of five patients.”
Source: Marketwatch
Filed under Blood Sugar Testing, Diabetes, Diabetes Drug, IDDM
